These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20415601)

  • 1. The future is today: emerging drugs for the treatment of erectile dysfunction.
    Albersen M; Shindel AW; Mwamukonda KB; Lue TF
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):467-80. PubMed ID: 20415601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for the treatment of erectile dysfunction.
    Peak TC; Yafi FA; Sangkum P; Hellstrom WJ
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):263-75. PubMed ID: 25740087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer phosphodiesterase inhibitors: comparison with established agents.
    McNamara ER; Donatucci CF
    Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact.
    Voznesensky I; DeLay KJ; Hellstrom WJ
    Expert Opin Pharmacother; 2016 Dec; 17(17):2281-2289. PubMed ID: 27677349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
    Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
    J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Yang L; Qian S; Liu L; Pu C; Yuan H; Han P; Wei Q
    Urol Int; 2013; 90(3):339-47. PubMed ID: 23221333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
    Dorsey P; Keel C; Klavens M; Hellstrom WJ
    Expert Opin Pharmacother; 2010 May; 11(7):1109-22. PubMed ID: 20402554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapeutic management of erectile dysfunction.
    Hawksworth DJ; Burnett AL
    Clin Pharmacol Ther; 2015 Dec; 98(6):602-10. PubMed ID: 26352006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
    Aversa A; Francomano D; Lenzi A
    Expert Opin Pharmacother; 2015 Apr; 16(5):625-8. PubMed ID: 25643866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double-Blind, Sham Controlled Study.
    Kitrey ND; Gruenwald I; Appel B; Shechter A; Massarwa O; Vardi Y
    J Urol; 2016 May; 195(5):1550-1555. PubMed ID: 26694904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of erectile function and responsiveness to phosphodiesterase type 5 inhibitors at different stages of streptozotocin-induced diabetes in rats.
    Cho SY; Park K; Paick JS; Kim SW
    J Sex Med; 2011 May; 8(5):1352-61. PubMed ID: 21054802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on emerging drugs for the treatment of erectile dysfunction.
    Milenkovic U; Campbell J; Roussel E; Albersen M
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):319-330. PubMed ID: 30507329
    [No Abstract]   [Full Text] [Related]  

  • 15. An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions.
    Ismail EA; El-Sakka AI
    Expert Opin Investig Drugs; 2024 Sep; 33(9):925-938. PubMed ID: 39096237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care.
    Costa P; Grandmottet G; Mai HD; Droupy S
    J Sex Med; 2013 Jul; 10(7):1850-60. PubMed ID: 23679019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and perspectives in erectile dysfunction in man.
    Mitidieri E; Cirino G; d'Emmanuele di Villa Bianca R; Sorrentino R
    Pharmacol Ther; 2020 Apr; 208():107493. PubMed ID: 31991196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex?
    McCabe MP; Althof SE
    J Sex Med; 2014 Feb; 11(2):347-63. PubMed ID: 24251371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
    Cai Z; Zhang J; Li H
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):119-128. PubMed ID: 30675707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.
    Lasker GF; Pankey EA; Kadowitz PJ
    Physiology (Bethesda); 2013 Jul; 28(4):262-9. PubMed ID: 23817801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.